Oxandrolone and Human Growth Hormone

Raiti, Salvatore

doi:10.1001/archpedi.1973.02110190483003

Cited by 31 publications

(4 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1971 ;Marti-: Icnncbcrg ct al. 1977;Raiti et al 1973;Royer et al 1970;Wolfe et al 1973), particularly when administered in a specific sequence (i.e. Furthermore whether final adult height is improved has not been established .…”

Section: Growth Disordersmentioning

confidence: 99%

Adverse Effects of Anabolic Steroids

Hickson

Ball

Falduto

1989

Med Toxicol Adverse Drug Exp

View full text Add to dashboard Cite

Anabolic steroids are used therapeutically for various disorders and as ergogenic aids by athletes to augment strength, muscular development, and to enhance performance. There is a wide range of concomitant temporary and permanent adverse effects with steroid administration. Several well-documented adverse actions of these hormones may develop rapidly within several weeks or less (i.e. altered reproductive function) or require up to several years of steroid intake (i.e. liver carcinoma). More recent studies indicate that glucose intolerance, insulin resistance, increased cardiovascular disease risk profiles, cerebral dangers, musculoskeletal injuries, prostate cancer, psychosis and schizophrenic episodes, among others, accompany anabolic steroid intake. There is, at present, no evidence to support the claim that athletes are less susceptible to adverse effects than those individuals receiving hormone treatment in a clinical setting. Based on the available information which has accumulated primarily from cross-sectional, short term longitudinal, and case studies, there is a need: (a) to develop a comprehensive battery of specific and sensitive markers of adverse effects, particularly those that would be able to detect the onset of adverse actions; and (b) to conduct controlled long term longitudinal studies in order to fully understand the extensiveness and mechanisms involved in the occurrence of adverse effects.

show abstract

Section: Growth Disordersmentioning

confidence: 99%

Adverse Effects of Anabolic Steroids

Hickson

Ball

Falduto

1989

Med Toxicol Adverse Drug Exp

View full text Add to dashboard Cite

show abstract

“…There have been only a few studies on the use of growth hormone (GH) in patients with Prader-Willi syndrome, and the numbers of patients involved have generally been small. However, GH was shown to have a positive effect on increasing height and decreasing weight in the majority of these patients (6,(8)(9)(10)(11) syndrome who were treated with GH at a dose of 0.1 IU/kg/day. In the first year of treatment, height SDS increased from -2.2 to -0.8, and weight SDS decreased from 3.5 to 2.4 (12).…”

mentioning

confidence: 99%

Effect of 6 months of growth hormone treatment in young children with Prader—Willi syndrome

et al. 1997

View full text Add to dashboard Cite

Nine prepubertal children with Prader—Willi syndrome were treated with growth hormone (GH; 24 IU/m2/week) for 6 months. Mean height increased by 0.8 SD and mean weight for height decreased by 0.7 SD over this 6‐month treatment period. Body fat, measured by dual‐energy X‐ray absorptiometry, decreased by 22.5% over the period of GH treatment, whereas fat‐free mass increased by 14%. These preliminary results indicate that GH is effective in increasing height and normalizing body composition in patients with Prader—Willi syndrome. □ Body composition, growth hormone treatment, Prader—Willi syndrome, growth

show abstract

“…An improvement of the growth rate by the combined therapy with hGH and anabolics has been described before in other groups of patients with GHD [14,17]. The influence on the bone age can be demonstrated by the increased bone age velocity.…”

Section: Discussionmentioning

confidence: 52%

Growth hormone deficiency and growth hormone therapy in Ullrich-Turner-Syndrome

Butenandt

1980

Klin Wochenschr

View full text Add to dashboard Cite

In a girl with Ullrich-Turner-Syndrome (gonadal dysgenesis 45, XO) and growth hormone deficiency, 10 U of human growth hormone/m2 body surface area/week increased the growth rate from 2.0 to 4.1 cm/year. Doses of up to 36 U/m2/week did not improve the growth rate in 4 girls with Ullrich-Turner-Syndrome who had normal plasma growth hormone concentration and increation. We conclude that growth hormone therapy is unsuccessful in dwarfism in Ullrich-Turner-Syndrome and should be reserved for patients with proven growth hormone deficiency.

show abstract

Oxandrolone and Human Growth Hormone

Cited by 31 publications

References 14 publications

Adverse Effects of Anabolic Steroids

Adverse Effects of Anabolic Steroids

Effect of 6 months of growth hormone treatment in young children with Prader—Willi syndrome

Growth hormone deficiency and growth hormone therapy in Ullrich-Turner-Syndrome

Contact Info

Product

Resources

About